AROTINOLOL

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H21N3O2S3
Molecular Weight	371.541
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(O)CSC1=NC(=CS1)C2=CC=C(S2)C(N)=O

InChI

InChIKey=BHIAIPWSVYSKJS-UHFFFAOYSA-N

InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)

HIDE SMILES / InChI

Molecular Formula	C15H21N3O2S3
Molecular Weight	371.541
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11675958
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/6200619

Arotinolol (INN, marketed under the tradename Almarl) is a medication in the class of mixed alpha/beta blockers. It is used in the treatment of high blood pressure and essential tremor. The recommended dosage is 10–30 mg per day.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 89 Target ID: CHEMBL2094118 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6200619	Antagonist 2849
Adrenergic receptor alpha 65 Target ID: CHEMBL2095203 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6200619	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11675958	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
Carteolol hydrochloride suppresses the generation of reactive oxygen species and rescues cell death after ultraviolet irradiation of cultured lens epithelial cells.	2010-10-12	21283534
Overview of essential tremor.	2010-09-07	20856604
Are adrenergic receptor blockers effective or contraindicated in pulmonary arterial hypertension?	2009-12	19940372
Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats.	2009-12	19822980
Effect of arotinolol on left ventricular function in patients with idiopathic dilated cardiomyopathy.	2007-12	18254186
Carvedilol, a nonselective beta-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro.	2007-04	17383596
Spectrofluorometric determination of some beta-blockers in tablets and human plasma using 9,10-dimethoxyanthracene-2-sodium sulfonate.	2005-04	15881605
Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.	2005-03	15734668
Pantothenate kinase-associated neurodegeneration initially presenting as postural tremor alone in a Japanese family with homozygous N245S substitutions in the pantothenate kinase gene.	2004-10-15	15465096
Relapse of Graves' disease in a patient with pheochromocytoma.	2003-12	14709850
Enantioselective determination of arotinolol in human plasma by HPLC using teicoplanin chiral stationary phase.	2003-10	14598329
A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor.	2003-08	12853233
Micellar electrokinetic capillary chromatography determination of +S and -R arotinolol in serum using UV detection and solid phase extraction.	2002-01	11748803
Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers.	2001-09	11675958
Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes.	2001-07	11478592
Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report.	2001-03	11325074
Effects of beta-adrenergic blockers with different ancillary properties on lipid peroxidation in hyperthyroid rat cardiac muscle.	1989-10	2575990
Synthesis and beta-adrenergic blocking action of a new thiazolylthiopropanolamine derivative.	1978-09	29117

Patents

Sample Use Guides

In Vivo Use Guide

10-20 mg twice daily for 4 weeks

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:52:52 GMT 2025` Edited by `admin` on `Wed Apr 02 07:52:52 GMT 2025`
Record UNII	394E3P3B99
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AROTINOLOL

Official Name

English

NSC-317940

Preferred Name

English

(±)-5-(2-((3-(TERT-BUTYLAMINO)-2-HYDROXYPROPYL)THIO)-4-THIAZOLYL)-2-THIOPHENECARBOXAMIDE

Systematic Name

English

arotinolol [INN]

Common Name

English

AROTINOLOL [MI]

Common Name

English

Arotinolol [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576